Chronic Spontaneous Urticaria: FDA Approves Dupilumab for Children Ages 2 to 11

The FDA expanded dupilumab’s chronic spontaneous urticaria indication to children aged 2 to 11 years on April 22, 2026. Pediatricians now have the first biologic option for young patients whose hives and itch persist despite H1 antihistamines.

April 23, 2026 · 4 min read

The Story at a Glance:

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria in children ages 2 to 11 on April 22, 2026 — the first biologic for this age group.
The label restricts use to children still symptomatic on H1 antihistamines (H1AH); it is added to, not substituted for, the antihistamine.
Approval rests on the LIBERTY-CUPID program in older patients (Studies A and C) plus pediatric pharmacokinetic data from the single-arm CUPIDKids study.
Dosing is weight- and age-based subcutaneous, every 2 or 4 weeks; injection-site reactions were the most common adverse event.

What Happened

The FDA expanded dupilumab’s chronic spontaneous urticaria indication to children aged 2 to 11 years on April 22, 2026. The decision extends the prior adult and adolescent (≥12 years) approval granted in 2025 and makes Dupixent (dupilumab), developed by Regeneron and Sanofi, the first biologic medicine cleared for this age group with this condition.

The label requires that children remain symptomatic despite H1 antihistamine treatment, the standard first-line therapy. Dupilumab is a fully human monoclonal antibody that blocks IL-4 receptor alpha, inhibiting signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) — two cytokines central to type 2 inflammation in chronic spontaneous urticaria.

This is the fifth type-2-inflammation–driven condition for which dupilumab is approved in children younger than 12, joining indications such as atopic dermatitis, asthma, eosinophilic esophagitis, and allergic fungal rhinosinusitis. The European Union granted a parallel pediatric CSU approval earlier in April 2026.

Why This Chronic Spontaneous Urticaria Approval Matters

Roughly 14,000 children in the United States have chronic spontaneous urticaria that remains symptomatic despite H1 antihistamines. International guidelines recommend second-generation H1 antihistamines as first-line, with dose escalation up to fourfold, then biologic therapy for refractory disease. Until now, the only biologic option in older patients was omalizumab, and pediatric data below age 12 were sparse.

Selection criteria for pediatric candidates mirror the trial enrollment: persistent itch and hives for more than 6 weeks, weekly Urticaria Activity Score (UAS7, range 0–42) ≥16, weekly Itch Severity Score (ISS7, range 0–21) ≥8, and continued symptoms despite standard H1 antihistamine dosing. UAS7 is a validated composite of itch and hives; ISS7 captures itch severity alone.

The label does not exclude children who have failed omalizumab, but the most robust efficacy data come from omalizumab-naive patients. Inducible urticaria — physical, cold-induced, or solar — was excluded from trials and remains off-label.

Key Numbers from the Chronic Spontaneous Urticaria Trials

Pediatric efficacy was established by extrapolation from the LIBERTY-CUPID phase 3 program (NCT04180488), supported by pharmacokinetic data from the single-arm CUPIDKids study in 18 children aged 2 to 11 years (20 total in this age group across the program).

Pooled Studies A and C (n=289, ≥6 years, omalizumab-naive): well-controlled disease (UAS7 ≤6) at week 24 in 43.1% of dupilumab vs 23.4% of placebo; odds ratio 3.0 (nominal P<0.0001).
Pooled complete response (UAS7 = 0): 30.6% on dupilumab vs 15.9% on placebo; odds ratio 2.8 (nominal P<0.001).
Pooled itch reduction at week 24: least-squares mean change in ISS7 −9.9 vs −6.7; difference −3.2 (nominal P<0.0001).
Study A primary endpoint (UAS7): least-squares mean change −20.5 vs −12.0; difference −8.5 (P=0.0003).
CUPIDKids steady-state pharmacokinetics: mean trough at week 24 was 91.1 ± 39.4 mcg/mL.

Pediatric dosing is weight- and age-based: ages 2–5 years receive 200 mg every 4 weeks (5 to <15 kg) or 300 mg every 4 weeks (15 to <30 kg) without a loading dose; ages 6–11 follow weight-based regimens with an initial loading dose. Injection-site reactions were the most common adverse event more frequent than placebo. No new safety signals appeared in children aged 2 to 11.

What Experts Are Saying

George D. Yancopoulos, MD, PhD, Regeneron’s board co-chair and a principal inventor of dupilumab, framed the approval as another expansion of the drug’s pediatric footprint. He speaks for the sponsor.

“This is the fifth of these indications now extended to young children.” — George D. Yancopoulos, MD, PhD, Regeneron co-chair; sponsor representative

Alyssa Johnsen, MD, PhD, global head of immunology development at Sanofi, separately characterized the prior treatment landscape for children under 12 as limited, with few options that targeted the type 2 inflammatory drivers of chronic spontaneous urticaria. She also speaks for the sponsor. Independent commentators have noted that omalizumab has long been the standard biologic for antihistamine-refractory CSU in older patients, but until this approval, pediatric biologic options below age 12 were sparse.

What’s Next for Chronic Spontaneous Urticaria Care

Active phase 3 investigations of dupilumab continue in chronic pruritus of unknown origin and lichen simplex chronicus, indications where regulatory authorization has not yet been sought. Specialty pharmacy availability and prior authorization workflows for pediatric CSU are likely to be the immediate access concerns; Regeneron and Sanofi distribute through their existing dupilumab patient support infrastructure.

For pediatric care, the open clinical questions are durability of response beyond 24 weeks, performance in omalizumab-experienced children below age 12 (where only adolescent and adult data are currently available), and whether earlier biologic intervention modifies the natural history of pediatric chronic spontaneous urticaria. Long-term safety surveillance through existing dupilumab registries will help fill these gaps.

Bottom Line

Identify candidates with chronic spontaneous urticaria whose itch and hives persist beyond 6 weeks despite second-generation H1 antihistamines at standard or up to fourfold doses.
Confirm baseline severity using UAS7 (≥16) and ISS7 (≥8); rule out inducible or physical urticaria, which is not in the label, and document antihistamine adherence and dose history.
Counsel families that dupilumab is add-on therapy — children should continue their H1 antihistamine, and live vaccines should be deferred during treatment.
Plan vaccinations early: complete age-appropriate immunizations before initiation where possible; treat pre-existing helminth infections and screen for ocular comorbidities given the dupilumab safety profile.
Set realistic expectations with families: in older trial cohorts, complete response (UAS7 = 0) was achieved by about 30% and well-controlled disease (UAS7 ≤6) by about 43% at 24 weeks — meaningful but not universal.

Sources

Regeneron Pharmaceuticals, Inc. Dupixent (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria. April 22, 2026. Regeneron Press Release — Dupixent Pediatric CSU Approval
Maurer M, Casale TB, Saini SS, et al. Dupilumab in Patients with Chronic Spontaneous Urticaria (LIBERTY-CSU CUPID): Two Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials. Journal of Allergy and Clinical Immunology, 2024. JACI — LIBERTY-CSU CUPID Studies A and B
Casale TB, Bernstein JA, Maurer M, et al. Dupilumab Improves Itch and Urticaria Activity: Pooled Results from LIBERTY-CSU CUPID Study A and Study C. Journal of Allergy and Clinical Immunology, 2025. JACI — Pooled Study A and C Pediatric Data
Contemporary Pediatrics editors. FDA Approves Dupilumab for Chronic Spontaneous Urticaria in Children 2 Years and Older. Contemporary Pediatrics, April 22, 2026. Contemporary Pediatrics — Dupilumab CSU Approval
HCPLive editors. FDA Expands Dupilumab to Children Aged 2 to 11 Years With Uncontrolled CSU. HCPLive, April 22, 2026. HCPLive — Pediatric Dupilumab CSU Coverage
Brooks M. FDA Approves Pediatric Urticaria Indication for Dupilumab. Medscape, April 23, 2026. Medscape — Pediatric CSU Indication
American Journal of Managed Care editors. FDA Approves Dupilumab for Young Children With Uncontrolled CSU. AJMC, April 23, 2026. AJMC — Dupilumab Pediatric CSU Approval